摘要
目的探讨RAS相关区域家族1A基因(RASSF1A)甲基化在前列腺癌诊断中的意义。方法收集已发表的关于RASSF1A基因甲基化在前列腺癌与前列腺增生症中报道的国内外文献,针对结果进行统计学综合(Meta)分析。采用优势比(OR)及95%置信区间(95%CI)评价疗效,统计学分析采用RevMan 4.2软件。结果共9篇文献符合纳入标准,包括前列腺癌组541例和前列腺增生组258例的RASSF1A甲基化研究结果,Meta分析显示,研究文献中总的OR值及95%CI均在垂直线的右侧(OR=6.39,95%CI为4.32～9.46),差异有统计学意义(P<0.01)。结论前列腺癌患者中存在高频率的RASSF1A高甲基化现象,将其应用于临床作为前列腺癌的诊断分子标志物,仍需大样本研究证据。
Objective To investigate the diagnostic role of Ras association domain family 1A （RASSF1A） gene methy- lation in prostate cancer.Methods Retrieved published comparative studies prostate cancer and prostatic hyperplasia for RASSF1A gene methylation,and pooled the data from eligible studies （Meta-analysis）.Odds ratio （OR） and its 95% confidence interval （95%C/） were used as the measurement parameter of the diagnosis of RASSF1A gene promoter methylation comparison.The statistical analysis were performed using RevMan 4.2 software.Results Pooling data from nine trials,including 541 patients with prostate cancer and 258 patients with prostatic hyperplasia,showed the total OR and 95%CI were in the right of the vertical line （OR=6.39, 95%CI was 4.32-9.46）,the difference was significant （P〈 0.01）.Conclusion There is a high frequency of RASSF1A hypermethylation in prostate cancer.Further study in large case-control need to be done to validate the possibility of RASSF1A hypermethylation as biomarkers in the diagnosis of prostate cancer.
出处
《中国当代医药》
2013年第27期10-12,15,共4页
China Modern Medicine
